A new study investigating the frequency and characteristics of sarcoid arthropathy, in which sarcoidosis is accompanied by joint disease, revealed that a majority of patients with sarcoidosis also have sarcoid arthritis. The study “The clinical characteristics of sarcoid arthropathy based on a prospective cohort study” was published in the…
News
Infliximab effectively treats neurosarcoidosis, but patients may see their disease return (relapse) over time, according to results of a new study. The study, “Long-Term Outcomes Of Refractory Neurosarcoidosis Treated With Infliximab,” was published in the Journal of Neurology. Neurosarcoidosis (sarcoidosis affecting the nervous system) may be resistant to…
While the protein osteopontin is elevated in the blood of people with sarcoidosis, the increased levels are not determined by known genetic factors, according to a recent study. Nevertheless, several DNA variants in the osteopontin gene were linked to specific disease characteristics, such as lung tissue involvement, fever, or significant weight…
MicroRNAs encased in small vesicles (exosomes) present in blood circulation may help identify sarcoidosis patients at risk of developing cardiac sarcoidosis (CS). The study “Exosomal MicroRNA for Detection of Cardiac Sarcoidosis” was published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM). “CS is…
Patients with sarcoidosis have more than twice the risk of bone fractures compared to healthy people, a finding most likely linked to the inflammatory nature of the disease. While glucocorticoids — the main treatment option for sarcoidosis — are known to cause osteoporosis, researchers at the Mayo Clinic in Rochester,…
Three patients developed subcutaneous sarcoidosis in their arm after receiving an injection, but symptoms disappeared after treatment with minocycline, a broad-spectrum antibiotic, according to a research report. James Abbott and colleagues at the University of Pennsylvania School of Medicine wrote the report, “Isolated Subcutaneous Sarcoid-Like Granulomatous Inflammation Occurring At Injection…
Understanding which molecules, genes and proteins are active or inactive in sarcoidosis patients may help explain differences in the disease’s severity from patient to patient, a study reported. The variations in these actions and inactions — which scientists call molecular differences — may also explain which organs sarcoidosis will impact.
Sarcoidosis patients may be at a higher risk of cardiovascular disease than the general population — especially if patients have previous heart conditions, smoke, are overweight, or have diabetes, a study reports. The findings were published in the European Respiratory Journal, in the article “Risk Of Cardiovascular Disease Among Patients With…
The bacteria causing tuberculosis (Mycobacterium tuberculosis) is also involved in sarcoidosis, confirms a study published in the International Journal of Infectious Diseases.
Sarcoidosis Patients Have Increased Risk of Hospital Infection, Finds Study That Spanned 35+ Years
Sarcoidosis patients are two times more susceptible to hospitalized infection than the general population, especially those treated with glucocorticoid therapy, according to results of a new study. The study, titled “Sarcoidosis Increases Risk Of Hospitalized Infection: A Population-Based Study 1976-2013,” was published in the journal Annals of the…
Recent Posts
- New AI model predicts sudden cardiac death risk better in cardiac sarcoidosis
- FSR invests $400K in 4 early-stage sarcoidosis research projects
- The questions of menopause mirror the uncertainty of sarcoidosis
- 7 new institutions join FSR alliance to improve treatment of sarcoidosis
- Simple blood test may predict cardiac sarcoidosis outcomes
- To scoot or not to scoot: Using a mobility aid with a dynamic disability
- Mobile app for breathing meditation may reduce sarcoidosis fatigue
- New report highlights unmet needs and treatment burdens in sarcoidosis
- Cardiac sarcoidosis symptoms at diagnosis help predict long-term risk
- Methotrexate is safer second-line sarcoidosis treatment than MMF